Zacks Investment Research
18 Jun 2026, 14:55 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Analysts have revised their earnings estimates for Surgery Partners (SGRY) upward. — Positive earnings revisions are typically a strong catalyst for stock price appreciation as they signal improving fundamentals.
+0.40The mean analyst price target for SGRY is $17.95, representing a 26.1% potential upside from its last closing price of $14.23. — While providing a bullish benchmark, the article notes price targets are often overly optimistic and less reliable than earnings revisions.
+0.20Which stocks this story touches
The stock has gained 5.5% in four weeks and has a positive mean price target upside of 26.1% with positive earnings estimate revisions.
Continue reading
6 related stories
Top 1 mover · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
2h ago
